IIT2017-05-MERIN-BLINHMCT: Blinatumomab Plus HLA-Mismatched Cellular Therapy (HMCT) for Relapsed/Refractory CD19+ ALL
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2020
Price : $35 *
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 03 Jan 2020 Status changed from not yet recruiting to recruiting.
- 04 Sep 2019 Planned initiation date changed from 1 Jul 2019 to 1 Dec 2019.
- 13 May 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jul 2019.